AOTMiT: Transparency Council will look into Covid-19 vaccine and osteoporosis drug, among others

During the session, it was scheduled:

1. Preparation of an opinion on the use of the medicinal product BIMERVAX - vaccine against COVID-19 (recombinant, with adjuvant).
2. Preparation of a position paper on the legitimacy of qualifying the service "Monitoring of cardiac function and therapy of dangerous ventricular arrhythmias with the use of a defibrillation vest" as a guaranteed benefit of outpatient specialized care.
3. Preparation of a position paper on the evaluation of the drug Evenity (romosozumabum) under the drug program "Treatment of women with severe postmenopausal osteoporosis with fracture (ICD-10: M80.0)."

Source: AOTMiT